Roche aims to 'underwhelm' with risdiplam price as it enters SMA rivalry with Biogen, Novartis — report

With their third-to-market spinal muscular atrophy drug risdiplam now cruising on the FDA’s VIP lane toward a May decision, Roche is thinking through its pricing strategy.